Original article by Kate Aubusson
The Age – Page: Online : 7-Apr-21
Data from AusVaxSafety shows that 49.7 per cent of Australians who had received the AstraZeneca or Pfizer vaccine by the end of March had experienced at least one mild side effect. Some 1.2 per cent were sufficiently concerned to see a doctor or go to a hospital’s emergency department. More than two-thirds of people who received their first dose of AstraZeneca’s vaccine reported an adverse event, and 25.4 per cent said they had to take some time off from work, study or their daily duties. Meanwhile, 36.3 per cent of people reported an adverse event after receiving their first dose of the Pfizer vaccine; some 4.3 per cent had to miss work, study or routine duties.
Original article by Tamsin Rose, Kieran Rooney
Herald Sun – Page: 11 : 6-Apr-21
The Australian Technical Advisory Group on Immunisation will meet on 7 April to discuss the future rollout of AstraZeneca’s COVID-19 vaccine. A 44-year-old Melbourne man was recently admitted to hospital with a rare blood clotting condition after receiving the vaccine. Acting Chief Medical Officer Michael Kidd says it is "likely" that the case is linked to the vaccine, but he adds that there is no evidence to suggest that the risk is sufficiently high to halt the rollout. Kidd stresses that the vaccination program is necessary as Australia will remain vulnerable to future outbreaks, particularly as its international borders re-open.
AUSTRALIAN TECHNICAL ADVISORY GROUP ON IMMUNISATION, AUSTRALIA. DEPT OF HEALTH, ASTRAZENECA PLC